Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
89bio, Inc. (ETNB)  
$8.86 0.11 (1.26%) as of 4:30 Thu 5/2


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 97,871,000
Market Cap: 867.14(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $6.66 - $22.03
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    : 20.2
Insider 6 Months    : 20.2
Insider 3/6 Months : 40.8
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Co.'s primary product candidate, pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia. FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. FGF21 analogs represent a class of drugs to treat NASH, because they not only address the liver manifestations, but also have an effect on the multiple co-morbidities that worsen NASH.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 1,350,000 1,350,000 1,350,000 7,862,717
Total Buy Value $20,722,500 $20,722,500 $20,722,500 $80,687,796
Total People Bought 1 1 1 2
Total Buy Transactions 1 1 1 5
Total Shares Sold 57,195 107,195 154,628 206,908
Total Sell Value $623,326 $1,183,326 $2,078,063 $2,842,845
Total People Sold 1 1 4 5
Total Sell Transactions 2 3 7 15
End Date 2024-02-01 2023-10-31 2023-05-02 2022-05-02

   
Records found: 89
  Page 3 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Le-Nguyen Quoc See Remarks   •       –      –    2022-02-17 4 A $0.00 $0 D/D 22,500 32,500     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2022-02-17 4 A $0.00 $0 D/D 22,500 32,500     -
   Le-Nguyen Quoc See Remarks   •       –      –    2022-02-05 4 D $5.23 $7,128 D/D (1,363) 31,137     -
   Martins Ryan Chief Financial Officer   •       –      –    2022-02-05 4 D $5.23 $5,345 D/D (1,022) 22,478     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2022-02-05 4 D $5.23 $7,128 D/D (1,363) 31,137     -
   Palekar Rohan Chief Executive Officer   •       •      –    2022-02-05 4 D $5.23 $21,380 D/D (4,088) 95,957     -
   Waisbourd Ram See Remarks   •       –      –    2022-02-01 4 AS $5.70 $39,900 D/D (7,000) 0 -38%     
   Waisbourd Ram See Remarks   •       –      –    2022-02-01 4 OE $1.93 $13,510 D/D 7,000 7,000     -
   Palekar Rohan Chief Executive Officer   •       •      –    2022-01-28 4 B $6.14 $15,350 D/D 2,500 45,845 2.81 -35%     
   Palekar Rohan Chief Executive Officer   •       •      –    2022-01-27 4 B $7.50 $37,500 D/D 5,000 43,345 2.81 -40%     
   Orbimed Israel Gp Ii, L.p. 10% Owner   –       –       •   2022-01-26 4 S $8.38 $180,019 I/I (21,482) 1,829,436 51%     
   Orbimed Israel Gp Ii, L.p. 10% Owner   –       –       •   2022-01-25 4 S $8.40 $412,364 I/I (49,091) 1,840,176 55%     
   Waisbourd Ram See Remarks   •       –      –    2021-12-16 4 AS $11.48 $80,360 D/D (7,000) 0 -79%     
   Waisbourd Ram See Remarks   •       –      –    2021-12-16 4 OE $1.93 $13,510 D/D 7,000 7,000     -
   Waisbourd Ram See Remarks   •       –      –    2021-11-16 4 AS $16.49 $115,430 D/D (7,000) 0 -78%     
   Waisbourd Ram See Remarks   •       –      –    2021-11-16 4 OE $1.93 $13,510 D/D 7,000 7,000     -
   Waisbourd Ram See Remarks   •       –      –    2021-10-18 4 AS $17.49 $122,430 D/D (7,000) 0 -74%     
   Waisbourd Ram See Remarks   •       –      –    2021-10-18 4 OE $1.93 $13,510 D/D 7,000 7,000     -
   Waisbourd Ram See Remarks   •       –      –    2021-09-16 4 AS $19.46 $136,220 D/D (7,000) 0 -68%     
   Waisbourd Ram See Remarks   •       –      –    2021-09-16 4 OE $1.93 $13,510 D/D 7,000 7,000     -
   Waisbourd Ram See Remarks   •       –      –    2021-08-16 4 AS $18.28 $127,960 D/D (7,000) 0 -26%     
   Waisbourd Ram See Remarks   •       –      –    2021-08-16 4 OE $1.93 $13,510 D/D 7,000 7,000     -
   Waisbourd Ram See Remarks   •       –      –    2021-07-16 4 AS $16.80 $117,600 D/D (7,000) 0 -13%     
   Waisbourd Ram See Remarks   •       –      –    2021-07-16 4 OE $1.93 $13,510 D/D 7,000 7,000     -
   Palekar Rohan Chief Executive Officer   •       •      –    2021-07-08 4 B $16.25 $32,500 D/D 2,000 37,000 2.81 10%     
  89 Records found
  1  2  3  4   
  Page 3 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us